Compugen Ltd. announced on October 13, 2025, that the abstract for its pooled analysis of COM701 in heavily pre-treated platinum-resistant ovarian cancer (PROC) patients was published by the European Society of Medical Oncology (ESMO). The analysis included 60 evaluable PROC patients from prior COM701 Phase 1 clinical trials.
The pooled data demonstrated that COM701 was well tolerated and showed consistent, durable responses, particularly in patients without liver metastases, suggesting potential efficacy in patients with lower disease burden. An additional year of follow-up data will be included in the full poster presentation at ESMO on October 18, 2025.
These results support the rationale for evaluating COM701 as maintenance therapy in earlier lines of treatment, aligning with the ongoing MAIA-ovarian trial in relapsed platinum-sensitive ovarian cancer. The interim analysis for the MAIA-ovarian trial, which has activated sites in the U.S., Israel, and France, is estimated for year-end 2026, with the company's cash runway extending into 2027.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.